ArticleScientific reports2026
Endothelial SP1 lactylation promotes bronchopulmonary dysplasia via regulation of Cdkn1a expression.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Bronchopulmonary dysplasia (BPD) is a major complication of prematurity, and endothelial dysfunction contributes to its pathogenesis. Although lactate metabolism is dysregulated in BPD, whether lactate-derived lysine lactylation contributes to endothelial dysfunction remains unknown. This study investigated the role of lactylation in endothelial injury and the involvement of SP1-Cdkn1a axis in BPD. We found that lactate levels and global lactylation levels were increased in both in vitro and in vivo models of BPD, accompanied by impaired endothelial proliferation, migration and angiogenic capacity. Integrated bioinformatic analysis identified Cdkn1a as a glycolysis-associated hub gene in BPD, and its upregulation in pulmonary vascular endothelial cells (PVECs) was confirmed experimentally. Subsequent Cdkn1a knockdown alleviated hyperoxia-induced endothelial dysfunction. In addition, inhibition of glycolysis reduced lactylation level in PVECs, suppressed Cdkn1a expression, and partially improved pulmonary microvascular injury. To explore the upstream mechanism, lactylome profiling identified SP1, a known transcription factor of Cdkn1a, as a lactylated candidate. Increased SP1 lactylation and enhanced binding at the Cdkn1a promoter were verified in PVECs from BPD mice. K640R mutation attenuated SP1-dependent Cdkn1a promoter activation. Overall, this study reveals the involvement of endothelial lactylation in pathogenesis of BPD and implicates the SP1-Cdkn1a axis as a potential therapeutic target.
Indexed as
Identifiers
42236853What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.